How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Oncology Drug Market
- By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Melanoma
- By Drug Class: Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors, Hormonal Therapies, Alkylating Agents, Antimetabolites
- By Therapy Type: Targeted Therapy, Immunotherapy, Chemotherapy, Hormone Therapy, Combination Therapy
- By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular
- By Mechanism of Action: VEGF Inhibitors, EGFR Inhibitors, PD-1/PD-L1 Inhibitors, CD20 Inhibitors, PARP Inhibitors
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Lung Cancer leads By Cancer Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 308 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Oncology Drug Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Cancer Type 6
Drug Class 6
Therapy Type 5
Route of Administration 4
Mechanism of Action 5
Companies profiled
Roche
Novartis
Pfizer
Bristol-Myers Squibb
Merck & Co.
AstraZeneca
Johnson & Johnson
Eli Lilly and Company
Amgen
Sanofi
Takeda Pharmaceutical Company
GlaxoSmithKline
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Roche
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bristol-Myers Squibb
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Johnson & Johnson
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Eli Lilly and Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Amgen
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sanofi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Takeda Pharmaceutical Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →GlaxoSmithKline
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AbbVie
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bayer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Regeneron Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$1,443M by 2033 · 6.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Lung Cancer53.8
- Breast Cancer7.4
- Colorectal Cancer6.0
- Prostate Cancer7.2
- Leukemia11.3
- Melanoma14.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$284.2M → $496.3M · 7.2%
Europe$198.0M → $350.9M · 7.4%
Asia Pacific$180.8M → $334.8M · 8.0%
Latin America$111.9M → $206.0M · 7.9%
Middle East and Africa$86.1M → $134.2M · 5.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.612026
6.632027
6.652028
6.662029
6.682030
6.692031
6.702032
6.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Roche18.7
- Novartis16.5
- Pfizer9.6
- Bristol-Myers Squibb11.0
- Merck & Co.8.3
- AstraZeneca8.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Cancer Type28.0%
Drug Class9.4%
Therapy Type15.7%
Route of Administration19.0%
Mechanism of Action27.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.6
- Europe23.1
- Asia Pacific22.0
- Latin America13.5
- Middle East and Africa8.8
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Roche | 83 | 86 | 95 | 86 | 91 | 92 | 89 |
| Novartis | 78 | 83 | 77 | 88 | 68 | 80 | 79 |
| Pfizer | 88 | 68 | 71 | 86 | 75 | 77 | 78 |
| Bristol-Myers Squibb | 82 | 64 | 82 | 70 | 71 | 72 | 74 |
| Merck & Co. | 61 | 58 | 68 | 71 | 58 | 73 | 65 |
| AstraZeneca | 47 | 49 | 54 | 70 | 56 | 57 | 56 |
| Johnson & Johnson | 51 | 61 | 49 | 40 | 50 | 42 | 49 |
| Eli Lilly and Company | 37 | 49 | 48 | 54 | 43 | 55 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Roche
- Novartis
- Pfizer
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Roche | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Novartis | ✓ | ◐ | ◐ | ◐ | ✓ | ◐ |
| Pfizer | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Bristol-Myers Squibb | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Merck & Co. | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| AstraZeneca | − | − | − | ◐ | ◐ | − |
| Johnson & Johnson | ◐ | ◐ | − | − | − | − |
| Eli Lilly and Company | − | − | − | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Roche89
2Novartis79
3Pfizer78
4Bristol-Myers Squibb74
5Merck & Co.65
6AstraZeneca56
7Johnson & Johnson49
8Eli Lilly and Company48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
RocheNovartisPfizer
Challenger1
Strong scale, closing on the leaders.
Bristol-Myers Squibb
Contender1
Focused players with pockets of strength.
Merck & Co.
Niche3
Specialists in a single segment or region.
AstraZenecaJohnson & JohnsonEli Lilly and Company
Go-to-market strategy
Land Cancer Type in North America, then scale across Oncology Drug Market — a $111M beachhead inside a $1.96B market.
Beachhead (SOM)$111Mobtainable near-term
Serviceable (SAM)$790Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Lung Cancer
Best fit — highest urgency & budget in Cancer Type.
Economic buyer77 fit
Breast Cancer
Strong fit — clear ROI and a fast path to value.
End user65 fit
Colorectal Cancer
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Cancer Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapy Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Cancer Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Oncology Drug Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation13%
Closed-won7%
$14.4KCAC
$73KLTV
5.1:1LTV : CAC
< 3 moCAC payback
Investment thesis
Oncology Drug Market is a resilient opportunity — $2.43B by 2033, compounding at 5.9%.
TAM · 2025$1.53Btoday
TAM · 2033$2.43Bforecast
CAGR5.9%2027–2033
Cumulative$17.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.43BTotal addressable market
SAM$955MServiceable available market
SOM$172MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.9% CAGR
Demand compounds through 2033, outpacing GDP across Cancer Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Cancer Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.43BLarge & growingTAM by 2033 at 5.9% CAGR
$955MServiceable nowreachable with today’s model
$172MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.89BBear3.8% CAGR
$2.43BBase5.9% CAGR
$3.11BBull7.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Oncology Drug Market — a $1.37B market by 2033. Plan: grow share from 9.8% to 16.3%.
Market size · 2033$1.37Btotal addressable
Market CAGR11.4%2027–2033
Target share16.3%from 9.8% today
Revenue ambition$223Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.8% | 16.3% | Behind |
| Revenue | $143M | $223M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 30.4% | 44.7% | On track |
| Customer retention | 86.7% | 94.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Cancer Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Cancer Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $24M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Cancer Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Sales deck · value proposition
Win the Oncology Drug Market conversation — a $5.93B market you can size, segment and defend in minutes.
Market size · 2033$5.93Btotal opportunity
Growth5.2%CAGR to 2033
Addressable buyers1,761+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Cancer Type
Goal Grow share in Cancer Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 3 mopayback period
$86K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
RocheNovartisPfizerBristol-Myers SquibbMerck & Co.AstraZenecaJohnson & JohnsonEli Lilly and Company+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Oncology Drug Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Oncology Drug Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Biologic Therapeutics Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B by 2033 · 4.44% CAGR
View reportSuperdisintegrants Market
Market size, share, segmentation and regional forecast.
$11.2B by 2033 · 6.23% CAGR
View reportBeta Blocker Market
Market size, share, segmentation and regional forecast.
$11.4B by 2033 · 4.09% CAGR
View reportHuman Vaccines Market
Market size, share, segmentation and regional forecast.
$4.5B by 2031 · 3.97% CAGR
View reportContraceptive Devices Market
Market size, share, segmentation and regional forecast.
$13.4B by 2033 · 3.39% CAGR
View reportNanoemulsions Market
Market size, share, segmentation and regional forecast.
$9.5B by 2033 · 9.37% CAGR
View reportOpioid Anesthetics Market
Market size, share, segmentation and regional forecast.
$12.0B by 2032 · 10.51% CAGR
View reportBiosimilar Monoclonal Antibodies Market
Market size, share, segmentation and regional forecast.
$4.9B by 2033 · 9.38% CAGR
View reportAnti-Retroviral Drugs Market
Market size, share, segmentation and regional forecast.
$8.1B by 2032 · 4.78% CAGR
View reportBone Morphogenetic Proteins Market
Market size, share, segmentation and regional forecast.
$12.5B by 2032 · 5.03% CAGR
View reportCellulite Treatment Market
Market size, share, segmentation and regional forecast.
$7.6B by 2033 · 10.27% CAGR
View reportOral Anti-Diabetic Drug Market
Market size, share, segmentation and regional forecast.
$10.1B by 2031 · 10.30% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.